GlobeNewswire by notified

Inside information: Aspo's new strategic portfolio vision

Share

Aspo Plc
Stock Exchange Release
Inside information
May 14, 2024, at 8:00 a.m.


Inside information: Aspo's new strategic portfolio vision

Aspo will pursue a new portfolio vision of forming two separate companies in the coming years: Aspo Compounder and Aspo Infra. Considering the diverging business models and strategies with different ESG agendas, ESL Shipping would belong to ‘Aspo Infra’ and Telko and Leipurin would belong to ‘Aspo Compounder’.

The business models between Aspo Compounder and Aspo Infra differ across multiple dimensions such as type of growth investments capex needs, business time span, funding needs, and ESG agenda, and will further diverge when implementing the selected business strategies.

Aspo’s ambition is to aim to reach EUR 1 billion in net sales and 8% of EBITA (*) in 2028. This ambition for year 2028 is split by business:

  • ESL Shipping: net sales of EUR >300 million and EBITA-% of 14% (Aspo Infra)
  • Telko: net sales of EUR >500 million and EBITA-% of 8% (Aspo Compounder)
  • Leipurin: net sales of EUR >200 million and EBITA-% of 5% (Aspo Compounder)

This financial ambition is estimated to require cumulated capex investment in the magnitude of EUR 350-400 million during 2024-2028, split approximately fifty-fifty between Aspo Infra and Aspo Compounder.

The approach and timing of the transformation are to be defined with the aim to maximise shareholder value. Different possible approaches will be considered, e.g. demerger, IPO, and full or partial sales. Timing will depend among others on growth investments, the financial performance of the businesses and market conditions. During the transformation process Aspo focuses on successful execution of the business strategies and improving the financial performance of the businesses.

(*) Operating profit excluding amortization of intangible assets (EBITA).

ASPO Plc
Rolf Jansson
CEO

Further information:
Rolf Jansson, CEO, tel. +358 400 600 264, rolf.jansson@aspo.com
Erkka Repo, CFO, tel. +358 405 827 971, erkka.repo@aspo.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Offentliggørelse af børsprospekt samt meddelelse om formue og antal investorer i andelsklasse Fairrente, kl n under Investeringsforeningen PortfolioManager30.5.2024 09:38:12 CEST | pressemeddelelse

Investeringsforeningen PortfolioManager offentliggør hermed opdateret fællesprospekt. Opdateringen sker som følge af, at andelsklassen Fairrente, kl n optages til handel på Nasdaq Copenhagen A/S med første handelsdag den 3. juni 2024. Der har været løbende emission i andelsklassen siden primo maj 2024. Nedenfor findes oplysninger om andelsklassens investorer, antal udstedte beviser samt formue per. d.d. AndelsklasseISINAntal investorerAntal cirkulerende andeleFormue kr. DKKFairrente, kl nDK0062840195 1013.3671.341.087 Prospektet er vedhæftet. Prospekt vil desuden kunne findes på foreningens hjemmeside portfoliomanager.dk Henvendelser vedrørende denne meddelelse kan rettes til undertegnede på tlf. 38 42 21 42. Med venlig hilsen Nina Trolle Boldt, adm. direktør Fundmarket A/S Vedhæftet fil Fællesprospekt_-_børsprospekt Fairrente kl n

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer30.5.2024 09:00:00 CEST | Press release

PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that earlier this month patients in France received the first doses of PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings: Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent Today’s news follows earlier announcements by Curium of the first doses for Greece in November 2023, and for 2024 first doses for Italy in February, for the Netherlands in March, and for Germany in May. Benoit Woessmer, PET Europe CEO at Curium commented, “We are extremely pleased

Interim financial report for 1 January - 31 March 2024 for FirstFarms A/S30.5.2024 09:00:00 CEST | Press release

Satisfactory start of 2024 FirstFarms has had a satisfactory start to the year. A number of significant events will have a positive impact on the Group going forward. FirstFarms has in the accounting period Q1-2024 realised: · A turnover of 104 mDKK (2023: 109 mDKK) · An EBITDA of 36 mDKK (2023: 33 mDKK) · An EBIT of 22 mDKK (2023: 22 mDKK) · A pre-tax result of 14 mDKK (2023: 20 mDKK) EBITDA has improved by 3.0 mDKK compared to the same period last year. The decrease in turnover is due to lower sale of previous years’ crops compared to Q1 2023. The lower pre-tax result compared to the same period last year is primarily due to a higher interest rate level, but also completed investments in 2023. CEO of FirstFarms, Anders H. Nørgaard, is satisfied with the Q1 results: "Our animal production has got off to a good start, and we have increased the turnover of pigs and milk by a total of 9 mDKK compared to the same period last year. "The low crop prices have continued into 2024. This means

Delårsrapport for 1. januar - 31. marts 2024 for FirstFarms A/S30.5.2024 09:00:00 CEST | pressemeddelelse

Tilfredsstillende start på 2024 FirstFarms har fået en tilfredsstillende start på året. En række væsentlige begivenheder får positiv betydning for koncernen fremadrettet. FirstFarms har i regnskabsperioden Q1-2024 realiseret: · En omsætning på 104 mDKK (2023: 109 mDKK) · Et EBITDA på 36 mDKK (2023: 33 mDKK) · Et EBIT på 22 mDKK (2023: 22 mDKK) · Et resultat før skat på 14 mDKK (2023: 20 mDKK) EBITDA er forbedret med 3,0 mDKK sammenlignet med samme periode sidste år. Faldet i omsætning skyldes lavere salg af tidligere års afgrøder i forhold til Q1 2023. Det lavere resultat før skat i forhold til samme periode sidste år, skyldes primært et højere renteniveau men også gennemførte investeringer i 2023 Administrerende direktør i FirstFarms, Anders H. Nørgaard, er tilfreds med Q1-resultatet: ”Vores animalske produktion er kommet godt fra start, og vi har løftet omsætningen på grise og mælk med samlet 9 mDKK i forhold til samme periode sidste år. ”De lave afgrødepriser er fortsat ind i 2024.

Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 202430.5.2024 08:30:30 CEST | Press release

Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May 30, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that a post-hoc analysis of the Phase 3 clinical study results for EPYSQLI™ (SB12), a biosimilar to Soliris1 (eculizumab), will be presented at the 29th European Hematology Association 2024 (EHA2024) Hybrid Congress held in Madrid, Spain and virtually, from June 13 to 16, 2024. SB12 has shown equivalent efficacy with reference eculizumab (ECU) by lactate dehydrogenase (LDH) and comparable safety, pharmacokinetics, pharmacodynamics, and immunogenicity profiles in paroxysmal nocturnal hemoglobinuria (PNH) through the pivotal Phase 3 study.2 The post-hoc analysis of SB12 pivotal Phase 3 study presented at EHA2024 compared the proportion of patients remaining transfusion-free (“transfusion avoidance”) among those treated with SB12 or ECU, respectively. Eculizumab is kn

HiddenA line styled icon from Orion Icon Library.Eye